Gladstone Institutional Advisory LLC Has $2.59 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gladstone Institutional Advisory LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 847.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,939 shares of the company’s stock after purchasing an additional 128,748 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Teva Pharmaceutical Industries were worth $2,594,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at about $30,000. UMB Bank n.a. grew its stake in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $52,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.1 %

Shares of NYSE TEVA opened at $18.46 on Friday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a 52-week low of $8.55 and a 52-week high of $19.08. The firm has a 50 day moving average price of $18.02 and a two-hundred day moving average price of $16.92. The stock has a market cap of $20.91 billion, a P/E ratio of -47.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TEVA. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.